» Articles » PMID: 17102158

Insulin Treatment and the Problem of Weight Gain in Type 2 Diabetes

Overview
Journal Diabetes Educ
Publisher Sage Publications
Specialties Endocrinology
Nursing
Date 2006 Nov 15
PMID 17102158
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Insulin therapy has been shown to benefit the prognosis in patients with type 2 diabetes, but its initiation and intensification is often delayed through concerns about hypoglycemia and weight gain. In addition, weight gain is linked to the pathophysiology of type 2 diabetes and contributes to the overall risk for adverse cardiovascular outcomes. This article attempts to summarize this issue and examine the options available for weight management.

Methods: A broad range of literature has been reviewed to distill important, consistent facts about insulin and weight gain and the options available for limiting the problem.

Results: Unfortunately, the great benefits of insulin therapy may be potentially undermined by weight gain. Weight gain is physiologically and psychologically undesirable, especially in patients with diabetes who are already overweight. The fear of weight gain with some medications contributes to psychological insulin resistance, which may discourage patients from commencing or following insulin regimens. However, new diabetes treatments and lifestyle interventions can be used to mitigate these problems.

Conclusions: The exact choice of insulin and oral medications and weight loss interventions are important considerations in the overall management of patients with type 2 diabetes. Changes in a patient's lifestyle, such as modifications to diet and implementing an exercise program, are first-line treatments for type 2 diabetes and can also counteract insulin-induced weight gain.

Citing Articles

Efficacy and safety of once-weekly insulin versus once-daily insulin in patients with type 1 and type 2 diabetes mellitus: an updated meta-analysis of randomized controlled trials.

Xue M, Shen P, Tang J, Deng X, Dai Z Front Endocrinol (Lausanne). 2024; 15:1459127.

PMID: 39629047 PMC: 11611561. DOI: 10.3389/fendo.2024.1459127.


Comparison of efficacy and safety of insulin degludec/liraglutide and insulin glargine U-100/lixisenatide in individuals with type 2 diabetes mellitus using professional continuous glucose monitoring.

Kawaguchi Y, Hajika Y, Rinka M, Masumoto K, Sawa J, Hamazaki K J Diabetes Investig. 2024; 15(5):598-607.

PMID: 38258482 PMC: 11060164. DOI: 10.1111/jdi.14151.


Retrospective Study of IDegLira, a New Fixed-Ratio Combination, in Japanese Patients With Type 2 Diabetes Mellitus: Analysis of Background Factors Affecting Effectiveness After 6 Months of Treatment.

Yamada H, Morimoto J, Funazaki S, Tonezawa S, Takahashi A, Yoshida M J Clin Med Res. 2023; 15(8-9):406-414.

PMID: 37822852 PMC: 10563818. DOI: 10.14740/jocmr4995.


The diabetes insulin self-management education (DIME) intervention for people with type 2 diabetes starting insulin: a pilot feasibility randomised controlled trial.

Winkley K, Sorsa T, Tian Q, Reece I, Fitzgerald C, Chamley M Pilot Feasibility Stud. 2023; 9(1):89.

PMID: 37237318 PMC: 10213567. DOI: 10.1186/s40814-023-01318-x.


Clinical and Genetic Predictors of Glycemic Control and Weight Loss Response to Liraglutide in Patients with Type 2 Diabetes.

Kyriakidou A, Kyriazou A, Koufakis T, Vasilopoulos Y, Grammatiki M, Tsekmekidou X J Pers Med. 2022; 12(3).

PMID: 35330424 PMC: 8955617. DOI: 10.3390/jpm12030424.